Show simple item record

dc.contributor.authorCraig, JPen_NZ
dc.contributor.authorRupenthal, IDen_NZ
dc.contributor.authorSeyfoddin, Aen_NZ
dc.contributor.authorCheung, IMYen_NZ
dc.contributor.authorUy, Ben_NZ
dc.contributor.authorWang, MTMen_NZ
dc.contributor.authorWatters, GAen_NZ
dc.contributor.authorSwift, Sen_NZ
dc.date.accessioned2019-09-09T21:50:23Z
dc.date.available2019-09-09T21:50:23Z
dc.date.copyright2017en_NZ
dc.identifier.citationBMJ Open Ophthalmology 2017;1:e000065. doi: 10.1136/bmjophth-2016-000065
dc.identifier.issn2397-3269en_NZ
dc.identifier.urihttp://hdl.handle.net/10292/12802
dc.description.abstractObjective To evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME). Methods and analysis In vitro phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for Staphylococcus aureus, and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for S. aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa with cyclodextrin-complexed and uncomplexed Manuka honey were determined. In vivo phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation. Results In vitro phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both S. aureus and S. epidermidis, but not P. aeruginosa. In vivo phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05). Conclusion Overall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects.
dc.publisherBMJ Publishing Groupen_NZ
dc.relation.urihttps://bmjophth.bmj.com/content/1/1/e000065en_NZ
dc.rights© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
dc.titlePreclinical Development of MGO Manuka Honey Microemulsion for Blepharitis Managementen_NZ
dc.typeJournal Article
dc.rights.accessrightsOpenAccessen_NZ
dc.identifier.doi10.1136/bmjophth-2016-000065en_NZ
aut.relation.articlenumbere000065en_NZ
aut.relation.issue1en_NZ
aut.relation.volume1en_NZ
pubs.elements-id324104
aut.relation.journalBMJ Open Ophthalmologyen_NZ


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record